A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : INH

Search Conditions:
Search Keyword : INH
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: INH
Appearance Frequency: 443 time(s)
Long forms: 99

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
isonicotinic acid hydrazide
(178 times)
Pharmacology
(22 times)
SM (7 times)
PAS (6 times)
PTZ (6 times)
1952 [Isonicotinic acid hydrazide (INH); antituberculous activity in mice; creation of resistant strains in vitro].
inhibin
(42 times)
Reproductive Medicine
(12 times)
FSH (9 times)
LH (7 times)
ACT (4 times)
1983 Effect of chronic administration of inhibin and testosterone on spermatogenesis in adult male rats.
inhibitor
(36 times)
Molecular Biology
(5 times)
Inh (3 times)
PLA2 (3 times)
CDP (2 times)
1986 Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
idiopathic neonatal hepatitis
(14 times)
Pediatrics
(5 times)
BA (4 times)
EHBA (4 times)
ALP (3 times)
1996 Relationships between clinical and histological profiles of non-familial idiopathic neonatal hepatitis.
intermittent normobaric hypoxia
(13 times)
Physiology
(7 times)
BA (2 times)
AH (1 time)
ANS (1 time)
1989 [Kinetics of oxygen metabolism in pregnant women with high risk of developing late toxemia during intermittent normobaric hypoxia].
inhalation
(9 times)
Toxicology
(2 times)
i.p (3 times)
AUC (2 times)
p.o (2 times)
1994 Dose and route dependency of metabolism and toxicity of chloroform in ethanol-treated rats.
Interdisciplinary Network Heart Failure
(9 times)
Cardiology
(5 times)
HF (5 times)
UC (3 times)
HNC (2 times)
2012 Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study.
Isolated nocturnal hypertension
(9 times)
Vascular Diseases
(4 times)
BP (5 times)
ABPM (2 times)
CKD (2 times)
2012 Summer does not always mean lower: seasonality of 24 h, daytime, and night-time blood pressure.
inhaled insulin
(8 times)
Endocrinology
(6 times)
PIR (2 times)
BG (1 time)
BIT (1 time)
2003 Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.
10  inhalation injury
(6 times)
Traumatology
(5 times)
AIS (2 times)
TBSA (2 times)
B/T (1 time)
1990 Experimental inhalation injury with concomitant surface burn: dextran resuscitation improves lung water and oxygenation.
11  inhibition
(6 times)
Neurology
(3 times)
WM (3 times)
ACT (2 times)
BRIEF (2 times)
2002 Inhibitory control of acquired motor programmes in the human brain.
12  infundibuloneurohypophysitis
(5 times)
Radiology
(2 times)
AH (1 time)
CDI (1 time)
DI (1 time)
2002 Correlation of high signal intensity of the pituitary stalk in macroadenoma and postoperative diabetes insipidus.
13  inhaled human insulin
(5 times)
Endocrinology
(2 times)
s.c (2 times)
CI (1 time)
OR (1 time)
2006 Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy.
14  Inhibins
(4 times)
Neoplasms
(3 times)
DCIS (1 time)
EC (1 time)
IDC (1 time)
2005 Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps.
15  inhA genes for isoniazid
(3 times)
Microbiology
(2 times)
MDR-TB (3 times)
RIF (3 times)
DMC (1 time)
2014 Detection of multi-drug resistance & characterization of mutations in Mycobacterium tuberculosis isolates from North- Eastern States of India using GenoType MTBDRplus assay.
16  inhA promoter for isoniazid
(3 times)
Communicable Diseases
(2 times)
RIF (2 times)
AMK (1 time)
CAP (1 time)
2013 Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
17  inhA, and ahpC for isoniazid
(3 times)
Anti-Bacterial Agents
(2 times)
RIF (2 times)
KAN (1 time)
OFX (1 time)
2004 Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines.
18  inhibited
(3 times)
Pharmacology
(1 time)
APV (1 time)
BIMO (1 time)
DNQX (1 time)
1993 Nociceptive responses in the neostriatum and globus pallidus of the anesthetized rat.
19  inhibitor isoniazid
(3 times)
Biology
(1 time)
MAOA (2 times)
PCa (2 times)
CCCP (1 time)
2017 Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid.
20  drug-induced hepatitis attributed to isoniazid
(2 times)
Pulmonary Medicine
(1 time)
CYP2E1 (1 time)
NAT (1 time)
NAT2 (1 time)
2007 Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
21  immunoinhibition
(2 times)
Chemistry, Clinical
(1 time)
AMI (1 time)
cTnT (1 time)
1988 Effect of creatine kinase-MM subtype composition on a CK-MB immunoinhibition assay.
22  Incheon North Harbor
(2 times)
Environmental Health
(2 times)
CHLs (1 time)
EqP (1 time)
HCHs (1 time)
2001 Contamination of polychlorinated biphenyls (PCBs) in sediments from Kyeonggi Bay and nearby areas, Korea.
23  intrathecal administration of isoniazid
(2 times)
Neurology
(1 time)
ADA (1 time)
Cl (1 time)
CSF (1 time)
2003 [A case of refractory tuberculous meningitis markedly improved by intrathecal administration of isoniazid (INH)].
24  (metol)-isonicotinic acid hydrazide
(1 time)
Chemistry Techniques, Analytical
(1 time)
MBTH (1 time)
NBS (1 time)
NIF (1 time)
1994 Spectrophotometric methods for the determination of nifurtimox in bulk form and pharmaceutical formulations.
25  C1-inhibitor
(1 time)
Allergy and Immunology
(1 time)
HAE (1 time)
HRQoL (1 time)
2012 C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.
26  I. STUDIES ON THE DEVELOPMENT OF HYDRAZID
(1 time)
Pulmonary Medicine
(1 time)
SM (1 time)
1965 [EXPERIMENTAL STUDIES ON THE DEVELOPMENT OF DRUG RESISTANCE IN VIVO. I. STUDIES ON THE DEVELOPMENT OF HYDRAZID (INH) AND STREPTOMYCIN (SM) RESISTANCE ON EXPERIMENTAL TUBERCULOSIS IN MICE].
27  idiopathic neonatal cholestasis
(1 time)
Gastroenterology
(1 time)
NPC (1 time)
2002 Niemann-pick disease type C in neonatal cholestasis at a North American Center.
28  immunohistochemistry
(1 time)
Cardiology
(1 time)
CgA (1 time)
CVF (1 time)
DCM (1 time)
2009 [Association between expression of chromogranin A and myocardial fibrosis in patients with dilated cardiomyopathy].
29  immunoinhibition assay
(1 time)
Military Medicine
(1 time)
CK-MB (1 time)
ELP (1 time)
IRMA (1 time)
1993 Clinical evaluation of a rapid immunoinhibition assay for creatine kinase-MB in suspected myocardial infarction.
30  in vivo potency of the frontline TB drugs isoniazid
(1 time)
Microbiology
(1 time)
MMP (1 time)
Mtb (1 time)
RIF (1 time)
2018 Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis.
31  in-house prepared isoniazid
(1 time)
Communicable Diseases
(1 time)
TB (1 time)
2006 Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.
32  In-house urine dipsticks for detection of isoniazid
(1 time)
Pulmonary Medicine
(1 time)
--- 2002 The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.
33  in-stent neointimal hyperplasia
(1 time)
Cardiology
(1 time)
Df (1 time)
IVUS (1 time)
Rd (1 time)
2002 Impact of the cross-sectional geometry of the post-deployment coronary stent on in-stent neointimal hyperplasia: an intravascular ultrasound study.
34  incisional hernia
(1 time)
General Surgery
(1 time)
AWH (1 time)
EH (1 time)
FH (1 time)
2013 Shared and nonshared familial susceptibility to surgically treated inguinal hernia, femoral hernia, incisional hernia, epigastric hernia, and umbilical hernia.
35  include high dose isoniazid
(1 time)
Pulmonary Medicine
(1 time)
anti-TB (1 time)
WHO (1 time)
2009 The clinical relevance of Mycobacterial pharmacogenetics.
36  increased the time to Cmax
(1 time)
Medicine
(1 time)
anti-TB (1 time)
DOTS (1 time)
EMB (1 time)
2014 Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients.
37  increasing 19-HETE by isoniazid
(1 time)
Pharmacology
(1 time)
19-HETE (1 time)
AA (1 time)
Ang II (1 time)
2015 19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy.
38  indicate the genetic markers of resistance to isoniazid
(1 time)
Microbiology
(1 time)
MTBC (1 time)
RIF (1 time)
RT-MTB (1 time)
2016 Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens.
39  Indirect neonatal hyperbilirubinemia
(1 time)
Pediatrics
(1 time)
AOR (1 time)
G6PD (1 time)
LED (1 time)
2018 Indirect neonatal hyperbilirubinemia in hospitalized neonates on the Thai-Myanmar border: a review of neonatal medical records from 2009 to 2014.
40  infectious necrotic hepatitis
(1 time)
Veterinary Medicine
(1 time)
--- 2018 Infectious necrotic hepatitis caused by Clostridium novyi type B in a horse: case report and review of the literature.
41  inhA -15 for the drug isoniazid
(1 time)
Anti-Bacterial Agents
(1 time)
MAS-PCR (1 time)
RIF (1 time)
2018 Detection of First-Line Drug Resistance Mutations and Drug-Protein Interaction Dynamics from Tuberculosis Patients in South India.
42  inhA are those most frequently responsible for isoniazid
(1 time)
Microbiology
(1 time)
Mtb (1 time)
2014 A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis.
43  inhA associated with isoniazid
(1 time)
Communicable Diseases
(1 time)
--- 2010 Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray.
44  inhA genes that are associated with isoniazid
(1 time)
Microbiology
(1 time)
LAM (1 time)
MIC (1 time)
TB (1 time)
2009 Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America.
45  inhA genes, resulting in isoniazid
(1 time)
Microbiology
(1 time)
MABA (1 time)
MDR (1 time)
Mtb (1 time)
2010 First insights into the genetic diversity of Mycobacterium tuberculosis isolates from HIV-infected Mexican patients and mutations causing multidrug resistance.
46  inhA is one of a target of isoniazid
(1 time)
Pharmacology
(1 time)
--- 2011 [Establishment and drug susceptibility test of isoniazid resistant Mycobacterium smegmatis].
47  inhA mutant isoniazid
(1 time)
Pulmonary Medicine
(1 time)
ETH (1 time)
LPA (1 time)
2013 Can inhA mutation predict ethionamide resistance?
48  inhA promoter
(1 time)
Medicine
(1 time)
MDR (1 time)
RIF (1 time)
2015 Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
49  inhA promoter and the ahpC-oxyR intergenic region for isoniazid
(1 time)
Anti-Bacterial Agents
(1 time)
AMK (1 time)
CAP (1 time)
FQ (1 time)
2015 Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.
50  inhA ribosomal binding site, which are responsible for isoniazid
(1 time)
Parasitology
(1 time)
RIF (1 time)
RT-PCR (1 time)
TB (1 time)
2012 Fast test for assessing the susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by real-time PCR.
51  InhA, a target shared with isoniazid
(1 time)
Pulmonary Medicine
(1 time)
ETH (1 time)
PTH (1 time)
2016 A review of the use of ethionamide and prothionamide in childhood tuberculosis.
52  inhA, and rpoB gene mutations underlying isoniazid
(1 time)
Communicable Diseases
(1 time)
RMP (1 time)
2008 Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey.
53  inhA, oxyR-ahpC and kasA associated with isoniazid
(1 time)
Anti-Bacterial Agents
(1 time)
--- 2008 Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India.
54  inhalable drug carrier for antitubercular drug isoniazid
(1 time)
Biomedical Engineering
(1 time)
DPPC (1 time)
2010 In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis.
55  Inhalable microparticles containing a large payload of isoniazid
(1 time)
Pulmonary Medicine
(1 time)
BAL (1 time)
IL (1 time)
Mtb (1 time)
2011 Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice.
56  Inhalable pulmonary delivery of isoniazid
(1 time)
Lung Diseases
(1 time)
NPs (1 time)
2019 Pulmonary Delivery of Isoniazid in Nanogel-Loaded Chitosan Hybrid Microparticles for Inhalation.
57  inhalation of isonicotinic acid hydrazide
(1 time)
Allergy and Immunology
(1 time)
ELISA (1 time)
INA (1 time)
1990 Detection of IgE antibodies specific to isonicotinic acid hydrazide and its metabolite by enzyme-linked immunosorbent assay and the mechanism of sensitization by inhalation or ingestion of this compound.
58  inhalational anaesthetic drugs
(1 time)
Anesthesiology
(1 time)
i.v (1 time)
LA (1 time)
MR (1 time)
1994 Evaluation of cost minimization strategies of anaesthetic drugs in a tertiary care hospital.
59  inhalational anesthesia
(1 time)
Clinical Medicine
(1 time)
BAL (1 time)
GA (1 time)
TIVA (1 time)
2015 Cost of general anesthesia during radical gastrectomy using different specifications of propofol: cost-minimization analyses.
60  inhalational inductions
(1 time)
Anesthesiology
(1 time)
LF (1 time)
TF (1 time)
2015 Occupational Chronic Sevoflurane Exposure in the Everyday Reality of the Anesthesia Workplace.
61  Inhaled
(1 time)
Pharmacology
(1 time)
INHC (1 time)
ORALC (1 time)
1999 Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.
62  inhaled regular insulin
(1 time)
Endocrinology
(1 time)
CV (1 time)
GIRs (1 time)
SC (1 time)
2002 Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
63  inherited
(1 time)
Neurology
(1 time)
AD (1 time)
GPi (1 time)
IID (1 time)
2017 Pallidal deep brain stimulation for dystonia: a long term study.
64  inhibin B
(1 time)
Rehabilitation
(1 time)
AFC (1 time)
AMH (1 time)
FSH (1 time)
2014 Quality of life in female cancer survivors: is it related to ovarian reserve?
65  inhibin N terminal 1-33 AA residue fragment
(1 time)
Biotechnology
(1 time)
--- 2005 [Construction, expression and purification of repeat fragment polymer of oInhibin alpha-subunit N terminal 1-33 fragment].
66  inhibin preparation
(1 time)
Reproductive Medicine
(1 time)
--- 1987 Effects of bovine follicular fluid inhibin on serum gonadotrophin concentrations in ewes during oestrus.
67  inhibin-alpha conjugated to human alpha globulin
(1 time)
Veterinary Medicine
(1 time)
--- 1993 Ovulatory and endocrine responses after active immunization of gilts against a synthetic fragment of bovine inhibin.
68  inhibited by the first-line antitubercular drug isoniazid
(1 time)
Microbiology
(1 time)
KasA (1 time)
SAR (1 time)
TB (1 time)
2018 Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.
69  inhibited pacing
(1 time)
Cardiology
(1 time)
CHF (1 time)
CI (1 time)
EF (1 time)
2008 Rate-responsive pacing in patients with heart failure: long-term results of a randomized study.
70  inhibiting M.tb as effectively as the anti-TB drug isoniazid
(1 time)
Biochemistry
(1 time)
CFU (1 time)
MDR (1 time)
TB (1 time)
2015 Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.
71  inhibition concentrations, when compared with first line drugs isoniazid
(1 time)
Biochemistry
(1 time)
RIF (1 time)
2010 Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents.
72  inhibition fraction of K(in)
(1 time)
Pharmacology
(1 time)
LDL (1 time)
PK/PD (1 time)
2006 Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
73  inhibition of Mycobacterium tuberculosis by the first-line antituberculosis drugs isoniazid
(1 time)
Microbiology
(1 time)
EMB (1 time)
2005 The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
74  inhibitors of cell wall synthesis such as isoniazid
(1 time)
Allergy and Immunology
(1 time)
ATB (1 time)
Mtb (1 time)
2016 Isoniazid-induced control of Mycobacterium tuberculosis by primary human cells requires interleukin-1 receptor and tumor necrosis factor.
75  inhibitory concentration of isoniazid
(1 time)
Microbiology
(1 time)
--- 1997 SYTO16 labelling and flow cytometry of Mycobacterium avium.
76  inhibitory effects due to the antituberculosis drug isoniazid
(1 time)
Bacteriology
(1 time)
CHP (1 time)
EMSAs (1 time)
MSWt (1 time)
2015 Inactivation of the organic hydroperoxide stress resistance regulator OhrR enhances resistance to oxidative stress and isoniazid in Mycobacterium smegmatis.
77  inhibitory events
(1 time)
Neurology
(1 time)
LT (1 time)
NS (1 time)
SUB (1 time)
1994 Membrane properties of physiologically classified rat dorsal horn neurons in vitro: correlation with cutaneous sensory afferent input.
78  insights into drug
(1 time)
Biochemistry
(1 time)
--- 2003 Reduced affinity for Isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance.
79  Institut National d'Hygiene
(1 time)
Public Health
(1 time)
CI (1 time)
HBsAg (1 time)
OR (1 time)
2019 Risk factors of hepatitis B virus surface antigen carriage and serological profile of HBsAg carriers in Lome Togo, 2016.
80  Institute of Health
(1 time)
Biology
(1 time)
--- 2006 Normal pathways: controlling isotopes and building biomedical research in postwar France.
81  intact nephron hypothesis
(1 time)
Drug Therapy
(1 time)
--- 2019 The intact nephron hypothesis as a model for renal drug handling.
82  intake reduced the mean Cmax
(1 time)
Medicine
(1 time)
anti-TB (1 time)
DOTS (1 time)
EMB (1 time)
2014 Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients.
83  interactions, the binding of the frontline anti-tuberculosis drug isoniazid
(1 time)
--- 2017 Examining the role of protein structural dynamics in drug resistance in Mycobacterium tuberculosis.
84  intervention nursing home
(1 time)
Medicine
(1 time)
--- 2017 A quality improvement initiative on the use of psychotropic drugs in nursing homes in Flanders.
85  into the activity of isoniazid
(1 time)
Microbiology
(1 time)
--- 1992 Isolation and characterization of isoniazid-resistant mutants of Mycobacterium smegmatis and M. aurum.
86  intracellular NAD level and a higher resistance to isoniazid
(1 time)
Biochemistry
(1 time)
NAD (1 time)
2015 Functional Characterization of Sirtuin-like Protein in Mycobacterium smegmatis.
87  Intractable nausea, vomiting and hiccups
(1 time)
Neurology
(1 time)
AQP4-Ab (1 time)
NMO (1 time)
2017 Clinical analysis of neuromyelitis optica presenting as intractable nausea, vomiting and hiccups.
88  intrahepatic hepatitis
(1 time)
Gastroenterology
(1 time)
BA (1 time)
MS/MS (1 time)
NICCD (1 time)
2013 [Characteristics of the plasma amino acid spectrum of neonatal intrahepatic cholestasis caused by citrin deficiency].
89  intrathecal isoniazid
(1 time)
Internal Medicine
(1 time)
LMCA (1 time)
2017 Intrathecal Isoniazid for Refractory Tuberculous Meningitis with Cerebral Infarction.
90  isolated night-time hypertension
(1 time)
Vascular Diseases
(1 time)
BP (1 time)
IDH (1 time)
2017 Is night-time hypertension worse than daytime hypertension? A study on cardiac damage in a general population: the PAMELA study.
91  isolated nocturnal hypertension on ambulatory measurement
(1 time)
Vascular Diseases
(1 time)
BP (1 time)
IDH (1 time)
2010 Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations.
92  isolates had various susceptibilities to isoniazid
(1 time)
Anti-Bacterial Agents
(1 time)
--- 2011 Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
93  isolates have been tested for susceptibility to isoniazid
(1 time)
Microbiology
(1 time)
AST (1 time)
EMB (1 time)
MGIT (1 time)
1999 Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.
94  isonicotinoylhydrazones, analogs of the clinically used anti-tuberculosis drug isoniazid
(1 time)
Biochemistry
(1 time)
SSA (1 time)
2002 Isonicotinoylhydrazone analogs of isoniazid: relationship between superoxide scavenging and tuberculostatic activities.
95  It has long been known that almost all isoniazid
(1 time)
Medicine
(1 time)
--- 1997 Isoniazid resistance and the point mutation of codon 463 of katG gene of Mycobacterium tuberculosis.
96  its high early bactericidal activity, isoniazid
(1 time)
Anti-Bacterial Agents
(1 time)
NAT2 (1 time)
PBPK (1 time)
PD (1 time)
2016 A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
97  izoniazid hydrazin
(1 time)
Medicine
(1 time)
--- 1959 Properties of Mycobacterium tuberculosis strains resistant to izoniazid hydrazin (INH).
98  mabA-inhA
(1 time)
Microbiology
(1 time)
AMK (1 time)
CAP (1 time)
KAN (1 time)
2012 Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.
99  N-alkyl-2-isonicotinoylhydrazine-1-carboxamides was synthesized from isoniazid
(1 time)
Chemistry
(1 time)
InhA (1 time)
MICs (1 time)
Mtb (1 time)
2018 New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.